Klaus Theede

Klaus Theede

Auto-generated profile, based on publicly available information

Klaus Theede

Gastro Unit, Medical Section Copenhagen University Hospital – Amager and Hvidovre Hvidovre Denmark

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2022 in eClinicalMedicine
Verified
Journal Article
Open access
MKMarianne Kiszka-Kanowitz
Marianne Kiszka-Kanowitz
KTKlaus Theede
Klaus Theede
STSandra Bohn Thomsen
Sandra Bohn Thomsen
Jacob Tveiten BjerrumJacob Tveiten Bjerrum
Jacob Tveiten Bjerrum
JBJørn Brynskov
Jørn Brynskov
AMAnette Mertz-Nielsen
Anette Mertz-Nielsen
Retrospective studies suggest that for patients with ulcerative colitis (UC) combination therapy with low-dose azathioprine and allopurinol (L-AZA/ALLO) may result in higher remission rates than monotherapy with azathioprine (AZA). We prospectively investigated the effects of these drugs for remission in patients with moderate-to-severe UC. Open-label, unblinded, randomised, controlled, investigator-initiated, multicentre study conducted at eight hospital sites in Denmark. Adult patients with established UC, who were steroid dependent/refractory, thiopurine naïve, had a normal thiopurine methyltransferase, and achieved remission with steroids or infliximab were eligible for inclusion. Patients were randomly assigned by the investigators (1:1) to 52 weeks of treatment with once daily oral AZA (median dose 50 mg) combined with ALLO 100 mg versus AZA monotherapy (median dose 200 mg), using a computer-generated randomisation list with blocks of six. The trial was open without masking. All randomised patients who received at least one dose of study drug were included in primary and safety analyses (intention to treat population). The primary outcome was steroid and infliximab free remission after 52 weeks, defined as a Mayo Score of ≤1 and no rectal bleeding. The trial is completed and is registered in ClinicalTrials.gov (ClinicalTrials.gov NCT03101800). Between January 9, 2017 and February 10, 2021, 47 patients were randomised to l-AZA/ALLO and 42 to AZA and received at least one dose of the study drug. After 52 weeks, 20 of 47 (43%) patients in the l-AZA/ALLO group and nine of 42 (21%) patients in the AZA group achieved remission (odds ratio 2·54 [95% CI 1·00 to 6.78, p < 0·048]). Fourteen patients (30%) in the l-AZA/ALLO group and 16 (38%) in the AZA group were withdrawn from the study due to adverse events. This study suggests that after one year l-AZA/ALLO therapy may be associated with a beneficial effect on steroid- and infliximab-free clinical remission in patients with moderate-to-severe UC and should be considered as first line therapy. Funding for AAUC was provided by The Capital Region of Denmark (Regionernes Medicinpulje (6062/16)).

10 August 2016 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
MKMarianne Kiszka-Kanowitz
Marianne Kiszka-Kanowitz
KTKlaus Theede
Klaus Theede
AMAnette Mertz-Nielsen
Anette Mertz-Nielsen
Background: Treating inflammatory bowel diseases (IBD) using thiopurines is effective; however, a high rate of adverse effects and lack of efficacy limit its use. Retrospective studies have suggested that treatment with low-dose thiopurines in combination with allopurinol is associated with higher remission rates and lower incidence of adverse events. Aim: To compare the rates of clinical remission and the rates of adverse events in IBD patients treated with either standard treatment with azathioprine or low-dose azathioprine in combination with allopurinol. Methods: A prospective, open-label study, randomizing thiopurine-naïve IBD patients with normal thiopurine methyltransferase to 24 weeks of treatment with either standard azathioprine dose or low-dose azathioprine and allopurinol. Results: A total of 46 patients with ulcerative colitis or Crohn’s disease were randomized. We conducted an intention to treat analysis and found a significant (69.6%) proportion of the patients treated with low-dose azathioprine in combination with allopurinol was in clinical remission without the need for steroid or biologic treatment at week 24 compared to 34.7% of the patients treated with azathioprine monotherapy (RR, 2.10 [95% CI: 1.07–4.11]). In the azathioprine group, 47.8% of the patients compared to 30.4% of the patients in the azathioprine–allopurinol group had to withdraw from the study due to adverse events (RR, 1.47 [95% CI: 0.76–2.85]) Conclusions: This study indicated that by changing the treatment strategy from standard weight-based dosing of azathioprine to weight-based low-dose azathioprine in combination with allopurinol, we can increase remission rates in patients with IBD.

9 April 2025 in Gut Pathogens
Verified
Journal Article
Open access
PDF file
IGIda Marie Bruun Grønbæk
Ida Marie Bruun Grønbæk
SSSofie Sofie
Sofie Sofie
SMSarah Mollerup
Sarah Mollerup
EHEsben Holm Hansen
Esben Holm Hansen
SPSarah Juel Paulsen
Sarah Juel Paulsen
APAndreas Munk Petersen
Andreas Munk Petersen
The aetiology of Crohn’s disease, a chronic inflammatory bowel disease, is multifactorial and not completely understood. However, the association with gut dysbiosis is well-established, and manipulation of the gut microbiota has gained interest as a treatment strategy. This study aimed to investigate the effects of the probiotic strain Bifidobacterium breve, Bif195™ (Bif195) on intestinal inflammation, symptoms, and the gut microbiome composition in patients with small intestinal Crohn’s disease. This was a randomised, double-blind, placebo-controlled trial. Thirty-three patients with small intestinal Crohn’s disease were assigned to eight weeks of treatment with Bif195 or placebo (1:1). The primary outcome was changes in bowel wall thickness measured by intestinal ultrasonography. Other outcomes were changes in symptom severity, quality of life, faecal calprotectin, fatigue, and specific inflammatory parameters on ultrasonography. Changes in the microbiome composition were also examined. Bif195 did not affect the bowel wall thickness in the small intestine compared to placebo. Nor did we observe effects on secondary or clinical explorative outcomes. Analysis of the gut microbiome showed that the relative abundance of B. breve rose during the intervention in the Bif195 group, but the result was statistically non-significant. Surprisingly, we observed a clustering of baseline microbiome data into two groups that differed in several aspects including a statistically significant difference in the incidence of previous bowel resections among the participants. Furthermore, changes in symptom scores after eight weeks of intervention were significantly different across the two microbiome groups, with an interaction effect of p = 0.04. Eight weeks of treatment with Bif195 did not affect clinical outcomes for Crohn’s disease. However, variations in baseline microbiome data influenced the results. This underscores the importance of assessing baseline microbiome data in intervention studies in Crohn’s disease. Clinicaltrials.gov NCT04842149

1 March 2025 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
GMGorm Roager Madsen
Gorm Roager Madsen
Rune WilkensRune Wilkens
Rune Wilkens
MAMohamed Attauabi
Mohamed Attauabi
JIJohan F K F Ilvemark
Johan F K F Ilvemark
KTKlaus Theede
Klaus Theede
JBJohan Burisch
Johan Burisch
Background and Aims: This study assesses the prognostic role of intestinal ultrasound (IUS) in determining the disease course of ulcerative colitis (UC) in the first year after diagnosis. Methods: A prospective, multicenter population-based inception cohort study was conducted on patients newly diagnosed with UC. Patients with left-sided or extensive UC underwent IUS assessments at diagnosis, 3 months, and 12 months, alongside symptomatic, biochemical, and endoscopic evaluations. Transmural remission was defined as bowel wall thickness ≤3 mm without color Doppler signal in all segments. Results: From May 2021 to April 2023, 193 patients with left-sided or extensive UC were included. Inflammatory findings on IUS at diagnosis were associated with symptomatic, biochemical, and endoscopic markers of inflammation, but not with diagnostic delay. IUS-detected inflammation at diagnosis was an independent predictor for colectomy within the first 3 months, with bowel wall thickness >6 mm as the optimal cutoff (odds ratio 38, 95% confidence interval, 8–270, P < .0001). Three months after diagnosis, 59% of patients achieved transmural remission, which was associated with higher rates of steroid-free clinical remission in all subsequent follow-ups, as well as a reduced need for steroids during follow-up (6% vs. 19%, P = .036). Furthermore, transmural remission at 3 months increased the likelihood of steroid-free clinical remission, as well as transmural and complete remission, at 12 months. Conclusions: Findings by IUS at the time of diagnosis predict early colectomy risk in UC. Our results underscore that transmural remission is a feasible treatment target in early UC, and significantly impacts the disease course.

28 August 2026 in JCC Plus
Verified
Journal Article
Open access
JBJohan Burisch
Johan Burisch
JSJakob B. Seidelin
Jakob B. Seidelin
MVMarianne Kajbæk Vester‐Andersen
Marianne Kajbæk Vester‐Andersen
SWSigne Wildt
Signe Wildt
KTKlaus Theede
Klaus Theede
JKJens Kjeldsen
Jens Kjeldsen
Background: Monitoring strategies for patients with inflammatory bowel disease (IBD) in remission vary widely in clinical practice, reflecting limited evidence and a lack of consensus. With increasing numbers of patients living long term with IBD, there is a need for rational, clinically meaningful approaches to remission‐phase monitoring. Methods: DK‐MONITOR was conducted as a national, multidisciplinary Delphi consensus study in Denmark during 2025–2026. Gastroenterologists and IBD nurses from centres providing specialist IBD care developed and voted on draft statements addressing the monitoring of Crohn's disease and ulcerative colitis in whom objective remission had previously been confirmed. Statements were evaluated using anonymous electronic voting, with consensus predefined as ≥ 70% agreement. All statements were discussed at a face‐to‐face national consensus meeting, and statements not achieving consensus were revised and re‐voted. Results: A total of 28 gastroenterologists and 19 IBD nurses participated. Fifty draft statements were evaluated in the first voting round; 25 were subjected to a second voting round, and 22 achieved final consensus. The consensus supports monitoring strategies based primarily on patient‐reported outcomes and biomarkers, with selective use of endoscopy, imaging and therapeutic drug monitoring. Routine use of invasive investigations in stable patients was generally discouraged. A structured, conservative monitoring approach was agreed for patients with mild Crohn's disease managed without maintenance therapy. No consensus was reached for monitoring strategies in ulcerative colitis treated solely with 5‐aminosalicylates. Conclusion: DK‐MONITOR provides a pragmatic, clinician‐oriented framework for monitoring patients with IBD in remission, emphasising biomarker‐based assessment, individualised follow‐up and avoidance of unnecessary investigations. Adaptation may be required before implementation in other healthcare settings.